Sanja Hald Jacobsen

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Bo Åhrén, Luís Masmiquel, Harish Kumar et al. · The Lancet Diabetes & Endocrinology · 2017 · 476 citations

Medicine, Pharmacology, Pharmacotherapy +15

Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years

Thomas Danne, Torben Biester, Kerstin Kapitzke et al. · The Journal of Pediatrics · 2016 · 122 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Phase 3 Trial of Concizumab in Hemophilia with Inhibitors

Tadashi Matsushita, Amy D. Shapiro, Aby Abraham et al. · New England Journal of Medicine · 2023 · 114 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial

Tilo Biedermann, Piotr Kuna, Petr Panzner et al. · Journal of Allergy and Clinical Immunology · 2019 · 113 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17